Lundbeck moves Lu AA39959 into clinical phase II for the treatment of patients with bipolar disorder
H. Lundbeck A/S strengthens its pipeline of pharmaceuticals inclinical development by initiating clinical phase II trials with LuAA39959. The decision is based on positive pre-clinical results aswell as positive conclusions of the phase I trials in healthyindividuals. Lu AA39959 is first-in-class with a unique target profile.Pre-clinical studies in animal models have shown anti-psychotic-likeas well as anti-depressant-like effects, and Lu AA39959 is expectedto show clear and convincing effects in patients with bipolardisorder (also called manic-depressive illness or manic